October 22, 2015 8:00am EDT
Download as PDF
MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (NYSE:OPK) announced today that its GeneDx business
unit has expanded its inherited cancer panel offerings and genetic tests
to include four additional genes.
The four genes are POLD1, POLE, SCG5/GREM1, and SMARCA4. Three of the
genes, POLD1, POLE and SCG5/GREM1, are associated with colon polyposis,
colon cancer and endometrial cancer; while SMARCA4 is associated with an
increased risk of a rare form of ovarian cancer. With the addition of
these genes to the inherited cancer testing portfolio, it is possible to
more effectively identify patients at risk. Once abnormalities are
identified, patients can work with their healthcare providers to
understand their specific cancer risk and what they can do to manage
that risk.
“The addition of these four genes to the genetic tests now available
from GeneDx can help in the diagnosis of rare syndromes associated with
increased risk of colorectal, endometrial, ovarian and other cancers,”
said Marc. D. Grodman, M.D., CEO of BioReference Laboratories Inc., a
subsidiary of OPKO.
The new gene panels and tests are available now for physicians to order
from the GeneDx website. For more information, please visit www.genedx.com
or email us at wecare@genedx.com .
About OPKO Health, Inc.
OPKO is a multi-national biopharmaceutical and diagnostics company that
seeks to establish industry leading positions in large and rapidly
growing medical markets by leveraging our discovery, development and
commercialization expertise and our novel and proprietary technologies.
For more information, visit http://www.opko.com .
This press release contains "forward-looking statements," as that
term is defined under the Private Securities Litigation Reform Act of
1995 (PSLRA), which statements may be identified by words such as
"expects," "plans," "projects," "will," "may," "anticipates,"
"believes," "should," "intends," "estimates," and other words of similar
meaning, including statements regarding expectations about our inherited
cancer testing portfolio and the additional genes we have added to our
tests, the ability to more effectively identify patients at risk for
cancer, accelerate the diagnosis of rare syndromes associated with
increased risk for different forms of cancer, as well as other
non-historical statements about our expectations, beliefs or intentions
regarding our business, technologies and products, financial condition,
strategies or prospects. Many factors could cause our actual activities
or results to differ materially from the activities and results
anticipated in forward-looking statements. These factors include those
described in our filings with the Securities and Exchange Commission, as
well as the risks inherent in funding, developing and obtaining
regulatory approvals of new, commercially-viable and competitive
products and treatments. In addition, forward-looking statements may
also be adversely affected by general market factors, competitive
product development, product availability, federal and state regulations
and legislation, the regulatory process for new products and
indications, manufacturing issues that may arise, patent positions and
litigation, among other factors. The forward-looking statements
contained in this press release speak only as of the date the statements
were made, and we do not undertake any obligation to update
forward-looking statements. We intend that all forward-looking
statements be subject to the safe-harbor provisions of the PSLRA.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151022005428/en/
Company
OPKO Health, Inc.
Tara Mackay, 305-575-4100
Investor
Relations
or
Media
Rooney & Associates
Terry
Rooney, 212-223-0689
or
Marion
Janic, 212-223-4017
or
Investors
LHA
Anne
Marie Fields, 212-838-3777
or
Bruce
Voss, 310-691-7100
Source: OPKO Health, Inc.
Released October 22, 2015
email Email Alerts
location_city Company Profile
contact_page Contacts
rss_feed RSS News Feed
account_tree Sitemap
Apply on OPKO Health (Ireland)’s careers page